The burden of diabetes and how challenges in diabetes care has led to technological advances, including the use of big data and connected devices.
How technological advances in diabetes can be translated into the treatment of growth hormone disease.
Key stages in the journey of a paediatric patient on growth hormone therapy, and the supporting role of digital health technologies.
Factors influencing treatment adherence and optimisation strategies.
How connected devices and digital health tools help to provide an ecosystem of care.
Panel Discussion 1.
Panel Discussion 2.
Overview & Learning Objectives
How can digital health solutions better support patients with growth hormone disease and their healthcare professionals? What can we learn from the advances in technology used in diabetes care and apply these to improve the management of growth hormone disease? What real-world evidence is there of the effectiveness of digital tools in everyday growth hormone disease practice?
In this activity, three leading experts discuss these questions and more, highlighting the potential future role of digital health technologies and how they may be integrated into clinical practice guidelines.
After watching this activity, participants should be better able to:
- To understand the challenges in diabetes care and how these have led to technological developments in continuous glucose monitoring and automated insulin delivery along with consensus guidelines and clinical decision support systems to better support HCPs.
- To identify opportunities for artificial intelligence tools and decision support systems in providing better care for growth hormone disorders.
- To understand the key stages in the journey of growth hormone therapy patients and how use of digital health tools and data analytics augmented with a multi-component patient support program can lead to better outcomes.
- To highlight how a personalized treatment approach combining technology innovation, along with patient and caregiver engagement can lead to better outcomes.
Faculty & Disclosures
Prof. Moshe Phillip
National Centre for Childhood Diabetes, Schneider Children’s Medical Center, Israel
Prof. Phillip is the Director of the Institute for Endocrinology and Diabetes at the Schneider Children’s Medical Center, and serves as Vice Dean for Research and Development and Chair of the Irene and Nicholas Marsh Fund for Endocrinology and Diabetes at Sackler Faculty of Medicine, Tel-Aviv University. Prof. Phillip is also co-chairman of the International Conference for Advanced Technologies and Treatments of Diabetes (ATTD), and has published more than 240 manuscripts and books.
Advisory Board Member for AstraZeneca, Eli Lilly, Insulet, Mannkind, Medtronic Diabetes, Pfizer, Sanofi, and DOMPE. Consulting Fees from Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi, Qulab Medical, Provention Bio, and Merck Healthcare KGaA. Research grant recipient (for the institute) from Dexcom, Eli Lilly, Insulet, Medtronic Diabetes, Novo Nordisk, Pfizer, Roche Diagnostics, Sanofi, DreaMed-Diabetes, NG Solutions, Dompe, Lumos, GWAVE, and OPKO Stock Owner with DreaMed-Diabetes and NG Solutions.
Dr Sandro Loche
Ospedale Pediatrico Microcitemico “A. Cao”, Cagliari, Italy
Dr Loche is the former Head of the Paediatric Endocrinology Unit at the Paediatric Hospital Microcitemico in Cagliari (Italy), has served as vice-president for the Italian Society for Paediatric Endocrinology and Diabetes (SIEDP/ISPED), and as President for the Regional section of the Italian Society of Paediatrics. Dr Loche has also served as Editor of the Journal of Endocrinological Investigation, is currently Associate Editor of Frontiers in Endocrinology, and has published over 200 articles, reviews and books.
Consulting/lecture fees and research support from Merck Healthcare KGaA, Pfizer, Sandoz, and Springer Healthcare
Prof. Antonio de Arriba
Hospital Universitario Miguel Servet and Universidad de Zaragoza, Zaragoza, Spain
Prof. Arriba specializes in Paediatric Endocrinology at at Miguel Servet Hospital and is also President of the Research Committee of the Aragon Health Research Institute, dedicated to promoting translational research and investigating the impact of diagnostic and therapeutic tools in daily practice.
Honoraria (lectures/advisory boards) from Merck Healthcare KGaA, Pfizer, Novo Nordisk, and Sandoz.